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Abstract 
Cone-beam CT (CBCT) scans utilized for image guided radiation therapy (IGRT) procedures have 
become an essential part of radiotherapy. The aim of this study was to assess organ and effective doses 
resulting from new CBCT scan protocols (head, thorax, and pelvis) released with a software upgrade of the 
kV on-board-imager (OBI) system. Influence of the scan parameters that were changed in the new protocols 
on the patient dose was also investigated. 
Organ and effective doses for protocols of the new software (V2.5) and a previous version (V1.6) were 
assessed using Monte Carlo (MC) simulations for the International Commission on Radiological Protection 
(ICRP) adult male and female reference computational phantoms. The number of projections and the mAs 
values were increased and the size of the scan field was extended in the new protocols. Influence of these 
changes on organ and effective doses of the scans was investigated. The OBI system was modelled in 
EGSnrc/BEAMnrc, and organ doses were estimated using EGSnrc/DOSXYZnrc. The MC model was 
benchmarked against experimental measurements. 
Organ doses resulting from the V2.5 protocols were higher than those of V1.6 for organs that were 
partially or fully inside the scans fields, and increased by (3 to 13)%, (10 to 77)%, and (13 to 21)% for the 
head, thorax, and pelvis protocols for both phantoms, respectively. As a result, effective doses rose by 14%, 
17%, and 16% for the male phantom, and 13%, 18%, and 17% for the female phantom for the three scan 
protocols, respectively. The scan field extension for the V2.5 protocols contributed significantly in the dose 
increases, especially for organs that were partially irradiated such as the thyroid in head and thorax scans and 
colon in the pelvic scan. The contribution of the mAs values and projection numbers was minimal in the dose 
increases, up to 2.5%. 
The field size extension plays a major role in improving the treatment output by including more markers 
in the field of view to match between CBCT and CT images and hence setting up the patient precisely. 
Therefore, a trade-off between the risk and benefits of CBCT scans should be considered, and the dose 
increases should be monitored. Several recommendations have been made for optimization of the patient 
dose involved for IGRT procedures. 
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1. Introduction  
Cone beam CT (CBCT) using a wide x-ray beam with a digital image plate is employed for image 
guided radiation therapy (IGRT) to improve positioning of the target (tumour) for radiotherapy. However, 
imaging procedures give an additional radiation dose to surrounding tissues so procedures need to be 
optimized (Alaei and Spezi, 2015, AAPM, 2007). CBCT scans used for IGRT can be acquired with 
megavoltage (MV) or kilovoltage (kV) energies, but kV images are preferred because of the superior contrast. 
The kV systems are commonly integrated into modern linear accelerators (linac). The kV systems used 
extensively in radiotherapy are the on-board-imager (OBI) (Varian Medical systems, Palo Alto, CA) and x-
ray volume imaging (XVI) (Elekta, Crawley, UK), and this investigation is based on the Varian OBI system. 
Since its introduction, the OBI has been developed, through improvements in system software and 
hardware to enhance performance. Default scan protocols are released in parallel with new software, which 
can be used by practitioners directly or modified to suit particular applications. Recently, a new software 
version (V2.5) and protocols have been released. Organ and effective doses resulting from a wide range of 
XVI scan protocols were assessed recently (Marchant and Joshi, 2017). The aim of this study is to use Monte 
Carlo simulations to evaluate organ and effective doses resulting from the recent OBI upgrade, and to 
compare the doses to a previous version (V1.6). It also aimed to investigate the influence of the changes in 
different scan parameters on the dose levels. 
2. Materials and Methods 
2.1. Scan protocols: 
The OBI system employed in the study was integrated into a TrueBeam linac. The technical and 
dosimetric properties of the system have been described in detail in previous studies (Abuhaimed et al., 2014, 
Abuhaimed et al., 2015). The OBI software of the TrueBeam linac installed initially was V1.5, and this has 
been followed by upgrades to V1.6, V2.0, and recently V2.5. The main purpose of the upgrades was to give 
better performance of the system in matching the patient position with the CT images used for the treatment 
plan by, for example, improving the image quality using an enhanced image reconstruction technique, or 
extending the scan field size to include more tissues and organs as markers for use in matching images. This 
study compares organ and effective doses given by V2.5 with those of V1.6 for the scan protocols utilized 
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commonly in the clinic for head, thorax, and pelvis scans. Parameters for these protocols are listed in Tables 
1 and 2. 
Table 1: Scan parameters of the default protocols implemented in V1.6.  
(a) Explained in figure 1 of (Abuhaimed et al., 2014). 
(b) X blades control the extent of the beam in the lateral direction (scan diameter) at the isocentre. 
(c) Y blades control the extent of the beam in the axial direction (beam width) at the isocentre. 
 
Table 2: Scan parameters of the default protocols implemented in V2.5. 
 
 
 
Scan parameter Head Thorax Pelvis 
X-ray voltage (kV) 100 125 125 
mA 20 20 80 
ms 20 20 20 
Projection numbers 367 660 660 
mAs 146.8 264 1056 
Scan rotation 200° 360° 360° 
Scan mode(a) Full-Fan Half-Fan Half-Fan 
Bowtie filter type(a) Full Half Half 
Trajectory Half Full Full 
X1 and X2 (mm)(b) –132, +132 –26, +239 –26, +239 
Y1 and Y2 (mm)(c) –99, +99 –99, +99 –99, +99 
Scan diameter (mm) 264 478 478 
Beam width (W) (mm) 198 198 198 
Scan parameter Head Thorax Pelvis 
X-ray voltage (kV) 100 125 125 
mA 15 15 60 
ms 20 20 20 
Projection numbers 500 900 900 
mAs 150 270 1080 
Scan rotation 200° 360° 360° 
Scan mode Full-Fan Half-Fan Half-Fan 
Bowtie filter type Full Half Half 
Trajectory Half Full Full 
X1 and X2 (mm) –140, +140 –34, +247 –34, +247 
Y1 and Y2 (mm) –107, +107 –107, +107 –107, +107 
Scan diameter (mm) 280 494 494 
Beam width (W) (mm) 214 214 214 
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The main differences between protocols of V1.6 and V2.5 are: 
1- Values of mAs per projection were reduced from 0.8 and 1.6 to 0.3 and 1.2 for the V2.5 protocols. 
However, the numbers of projection were increased by 133 and 240 projections for the head and 
body protocols, respectively, which led to an increase in mAs values by ~2.3%.  
2- The dimensions of the scan fields were extended by 16 mm in both axial (along the patient) and 
lateral directions. 
2.2. Assessment of organ and effective doses: 
Monte Carlo (MC) simulations were employed to assess organ doses resulting from V1.6 and V2.5 
CBCT scans for the International Commission on Radiological Protection (ICRP) adult male and female 
reference computational phantoms (ICRP, 2009). The MC simulations were run using BEAMnrc/EGSnrc 
and DOSXYZnrc/EGSnrc user codes (V2016) (Rogers et al., 1995, Kawrakow and Rogers, 2000, Walters et 
al., 2017). The MC calculations required to assess the doses were carried out in two main stages described in 
the following sub-sections: 
2.2.1. Simulation of the kV source: 
BEAMnrc user code was utilized to model the kV beam generated based on components of the OBI 
system, using elemental properties and dimensions of the components obtained from Varian. The MC model 
was validated against experimental measurements and this has been reported in detail in previous studies 
(Abuhaimed et al., 2014, Abuhaimed et al., 2015).  
The MC model was used to simulate kV beams for the scan protocols V1.6 (Table 1) and V2.5 (Table 
2). The parameter ISOURCE = 10 (Parallel Circular Beam Incident from Side) was employed to run 1.0×1010 
histories for each beam. Simulation of the kV beam in BEAMnrc requires only the field size and the bowtie 
type for each protocol, while running the simulations in DOSXYZnrc requires all the other parameters such 
as mAs and projection numbers. Figure 1 shows the difference between the scan fields for the V1.6 and V2.5 
head and body (thorax and pelvis) protocols. Since dimension of the scan field for the thorax and pelvis 
protocols is identical, but different from that of the head (Tables 1 and 2.), two kV beams for each version 
can be used, i.e. one for the head protocol and the other for the body protocols. Therefore, the two electron 
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energies of 100 keV and 125 keV were applied to generate two beams for V1.6 (Figure 1 a and b) and two 
for V2.5 (Figure 1 c and d).  
(a) V1.6 Head (c) V2.5 Head 
 
 
(b) V1.6 Body (Thorax and Pelvis) (d) V2.5 Body (Thorax and Pelvis) 
 
 
Figure 1: Dimension of the scan fields at an isocentre of 100 cm (a and b) for the V1.6 head and body (thorax 
and pelvis) protocols, respectively, and (c and d) for V2.5 (Tables 1 and 2). (a and c) represent the full fan 
used for the head scans, while (b and d) show the half-fan applied for the body scans.  
 
The cut off energy for photon transport (PCUT) and the low energy thresholds for creation of secondary 
photons (AE) were set to 1 keV. However, values for the corresponding parameters (ECUT) and (PE) for 
electrons were set to 516 keV, which is just above the electron rest mass energy. As the range of secondary 
electrons with energies of 100 keV and 125 keV inside the phantoms is small, e.g. the range of an electron 
in an adipose tissue, which has the lowest density in the body (0.92 g/cm3), is 0.15 mm for 100 keV and 0.22 
mm for 125 keV (NIST, 2017), the proportion of secondary electrons crossing a voxel boundary is extremely 
y axis 
x axis 
Y2 = -99 mm 
Y1 = 99 mm 
X1 = -132 mm X2 = 132 mm 
x axis 
y axis 
Y1 = 107 mm 
Y2 = -107 mm 
X1 = -140 mm X2 = 140 mm 
y axis 
x axis 
Y2 = -99 mm 
Y1 = 99 mm 
X1 = -26 mm X2 = 239 mm 
x axis 
y axis 
Y1 = 107 mm 
Y2 = -107 mm 
X1 = -34 mm X2 = 247 mm 
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small, as the voxel sizes are 2.1 × 2.1 × 8.0 mm3 for the male phantom and 1.8 × 1.8 × 4.8 mm3 for the female 
phantom. As a result, (ECUT) and (PE) can be set to any energy higher than the x-ray peak voltage. This 
modification results in deposition of the doses resulting from secondary electrons at the interaction sites (i.e 
original places), which minimizes the simulation time required to track trajectories and interactions of each 
secondary electron. 
The directional bremsstrahlung splitting technique, which improves the efficiency of MC simulations 
(Kawrakow et al., 2004, Mainegra-Hing and Kawrakow, 2006), was applied with a splitting number 
(NBRSP) set to 2×104. Spin effects, photoelectron angular sampling, Rayleigh scattering, atomic relaxations, 
and electron impact ionization were turned on. The algorithms EXACT and PRESTA-II were employed for 
the boundary crossing and electron-step, respectively. Data of Koch and Motz (KM) and the National Institute 
of Standards and Technology (NIST) were used for bremsstrahlung angular sampling and cross sections, 
respectively. The XCOM-NIST data were used for photon cross sections, and simple and Bethe-Heitler (BH) 
data were selected to pair angular sampling and pair cross sections, respectively. The four kV beams 
generated by BEAMnrc were stored in files known as phase space (PHSP) files at a source-surface-distance 
(SSD) of 50 cm. 
2.2.2. Assessment of absorbed dose: 
The MC model developed and validated in the first step (section 2.2.1) was also calibrated to calculate 
absolute absorbed dose for 100 kV and 125 kV x-ray beams. The method used to calibrate the model was 
reported in detail in (Martin et al., 2016), and was used to develop two energy-based calibration factors (𝐹𝑀𝐶) 
for 100 kV and 125 kV, which are used for the head and body protocols, respectively.  
The PHSP files obtained in the first step were moved to the user code (DOSXZYnrc) to assess organ 
doses resulting from each scan protocol listed in Tables 1 and 2. First, the ICRP male and female phantoms 
were converted to DOSXZYnrc format using a MATLAB code developed in house. Over 140 organs and 
tissues were defined in DOSXZYnrc, made up of 53 media of different elemental compositions and densities. 
The method used to covert and define the phantoms was reported in detail in (Martin et al., 2016). Second, 
the PHSP files were used as kV sources in DOSXZYnrc using ISOURCE = 8 (Phase-Space Source Incident 
from Multiple Directions). The centre of each phantom was placed at a source-isocentre-distance (SID) of 
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100 cm, so a distance of 50 cm along the beam axis was set between the positions of phantoms and the PHSP 
files. The centre of the head scan was set at mid-point of the head, while centres of the thorax and pelvis 
scans were at the mid-points of the lung and the pelvis of each phantom. 
Twelve simulations (six per phantom) using V1.6 and V2.5 protocols were run, each with different 
projection numbers and scan rotation as listed in Tables 1 and 2. In order to obtain statistical uncertainties 
<1% for organs and tissues that were irradiated fully by the primary beam, some 10×1010 and 1.5×1010 
histories were run for the male and female phantoms, respectively. Outputs of these simulations given in 
(3ddose) format were analysed using a MATLAB code developed in house to extract the mean absorbed dose 
in 3D for each organ and tissue as described in (Martin et al., 2016). Subsequently, the organ and tissue doses 
(𝐷𝑂,𝑇) were assessed as: 
𝐷𝑂,𝑇 =  𝐷𝑀𝐶  × 𝐹𝑀𝐶  × 𝑚𝐴𝑠 (1) 
where 𝐷𝑀𝐶  is the mean absorbed dose obtained from the MC simulations, 𝐹𝑀𝐶  is the calibration factor, and 
𝑚𝐴𝑠 depends on the protocol of interest. Effective doses (𝐸) for each protocol were then estimated using 
tissue weighting factors recommended by ICRP 103 (ICRP, 2007). For simplicity, “organ doses”, which 
refers to organ and tissues doses in the phantoms, will be used in subsequent sections in order to allow overall 
comparisons in dose levels to be made.   
2.2.3. Assessment of the influence of changes in different scan parameters: 
Six additional simulations were run (three per each phantom) using the head, thorax, and pelvic V2.5 
protocols to investigate the influence of the projection numbers and the associated increase in mAs values, 
on organ and effective doses. The scan parameters listed in Table 2 were used, except that the projection 
numbers and mAs values were set to those used for the V1.6 protocols (Table 1). The influence of the scan 
field extension by 16 mm in the axial and lateral directions was also investigated. This was achieved by using 
the V2.5 scan protocols to run six further simulations (three per each phantom), with the beam width and 
scan diameter set to the values used for the V1.6 protocols.  
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3. Results and Discussion 
3.1. Organ and effective doses: 
Organ doses resulting from CBCT scans using V1.6 and V2.5 scan protocols are given in Tables 3 to 5. 
The effective doses for the V2.5 protocol for the male phantom were 14%, 17%, and 16% higher for the head, 
thorax, and pelvis protocols, respectively, and for the female phantom were 13%, 18%, and 17% higher, 
respectively. The dose variations between the male and female phantoms for all protocols were mainly due 
to the differences in shape, size, and length of the phantoms and differences in the proportions of the organs 
irradiated. As a result, the dose variations can clearly be seen in the dose volume histograms (DVHs) resulting 
from the two versions for some organs (Figures 2 to 4). These show the proportion of the maximum dose 
received by different parts of the organ or tissue. The influence of these differences has been reported in 
various studies (Morant et al., 2013, Zhang et al., 2012, Zhang et al., 2013) and discussed in (Martin et al., 
2016).  
3.1.1. Head protocols: 
The organ with the largest difference in dose between the two software versions was the thyroid as the 
new field size includes more of both the male and female thyroids. The dose to the female thyroid is 
substantially greater, because the standard field size used covers a greater proportion of the thyroid (Figure 
2). The dose to the brain was 13% higher for both phantoms (Table 3), resulting from the broadening of the 
field size to include a greater proportion of the brain tissue, while doses to the oral mucosa and salivary 
glands were only increased by 3%, primarily due to the increase in mAs.  
  
Page 9 of 27 AUTHOR SUBMITTED MANUSCRIPT - JRP-100958.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cri
pt
10 
 
Table 3: Organ and effective doses for the adult male and female ICRP phantoms resulting from the V1.6 
and V2.5 head protocol (Tables 1 and 2).  
Head Male (mGy) Female (mGy) 
Organ / Tissue V1.6 V2.5 V1.6 V2.5 
Lymph nodes in field(1) 5.45 5.75 7.02 7.26 
Salivary glands 4.67 4.83 5.46 5.64 
Bone marrow in field(1) 4.13 4.52 6.15 6.64 
Lymph nodes in ET region 3.96 4.23 5.11 5.29 
Skin in field(1) 3.43 3.71 3.65 3.92 
Brain 3.14 3.55 3.43 3.87 
Extrathoracic (ET) region 2.37 2.5 3.69 3.81 
Oral mucosa 2.31 2.39 3.41 3.52 
Spinal cord 1.7 1.83 2.22 2.34 
Eye 1.15 1.2 1.1 1.15 
Eye lenses 0.97 1.02 1.02 1.06 
Thyroid 0.89 1.24 2.2 2.63 
Bone marrow (red) whole body 0.75 0.82 1.39 1.55 
Oesophagus 0.56 0.67 0.85 0.95 
Bone surface 0.45 0.49 0.85 0.94 
Lymph nodes 0.39 0.43 0.5 0.54 
Lymph nodes in TR region 0.34 0.47 0.9 1.04 
Skin whole body 0.29 0.32 0.33 0.36 
Muscle 0.26 0.28 0.29 0.32 
Remainder Tissues 0.25 0.27 0.28 0.31 
Thymus 0.22 0.27 0.35 0.41 
Lung 0.09 0.1 0.17 0.2 
Heart 0.05 0.06 0.1 0.11 
Breast 0.02 0.02 0.07 0.07 
Spleen 0.02 0.01 0.03 0.02 
Liver 0.02 0.01 0.03 0.02 
Stomach 0.01 0.01 0.02 0.01 
Adrenals 0.01 0.01 0.02 0.01 
Effective dose (mSv) 0.28 0.32 0.45 0.51 
(1)Skin, bone marrow and lymph nodes inside the head region. 
Organ doses to the gall bladder, kidneys, pancreas, prostate / uterus, small intestine, gonads (testes / ovaries), 
and urinary bladder were each 0.01 mGy. 
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Figure 2: Dose volume histogram (DVH) for a selection of organs resulting from the V1.6 and V2.5 head 
protocol (Tables 1 and 2) for the male (M) and female (F) ICRP phantoms. 
 
3.1.2. Thorax protocols: 
Doses for the majority of organs in the female phantom were (2 to 53)% greater than for the male, 
because of the larger proportion in the smaller body that were included in the field (Table 4, Figure 3). The 
increases in organ doses for the new thorax protocols were higher than for other protocols. The thyroid dose 
increased by 49% for the male and 77% for the female phantom. The large increase for the female occurred 
because part of the phantom came within the primary beam, receiving a dose of >15 mGy (Figure 3). The 
dose variations for organs that were fully inside the scan field of both versions such as lung, breast, heart, 
thymus, and oesophagus were between 10 and 19% for both phantoms. These variations were due largely to 
an extension of the field, which exposed a greater proportion of the organs (Figure 3). Moreover, the use of 
larger scan fields with higher projection numbers and mAs values led to an increase in scattered radiation 
from the organs and tissues that were covered by the primary beam and those at the edge of the scan field. 
The impact of this is more obvious for the body scans than for those of the head due to the size of the trunk.   
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Table 4: Organ and effective doses for the adult male and female ICRP phantoms resulting from the V1.6 
and V2.5 thorax protocol (Tables 1 and 2). 
Thorax Male (mGy) Female (mGy) 
Organ / Tissue V1.6 V2.5 V1.6 V2.5 
Thymus 11.56 13.79 13.48 14.79 
Heart 10.36 11.59 12.86 14.32 
Lung 7.89 8.99 9.9 11.29 
Lymph nodes in TR region 7.65 9.05 8.82 10.68 
Breast 7.55 8.32 10.15 11.19 
Bone marrow in field(1) 6.8 8.17 8.33 9.97 
Oesophagus 6.44 7.54 8.12 9.65 
Stomach 3.57 4.5 2.8 3.64 
Spleen 3.53 4.53 3.41 4.61 
Liver 3.3 4.27 4.07 5.33 
Lymph nodes in field(1) 3.16 3.74 3.71 4.44 
Spinal cord 3.16 3.81 3.74 4.5 
Lymph nodes 2.76 3.27 3.11 3.71 
Bone marrow (red) whole body 2.61 3.14 3.02 3.62 
Thyroid 2.61 3.89 3.37 5.96 
Skin in field(1) 2.12 2.47 2.72 3.17 
Bone surface 1.61 1.94 1.9 2.27 
Adrenals 1.58 2.02 1.71 2.22 
Remainder Tissues 1.38 1.61 1.58 1.86 
Gall bladder 1.29 1.67 1.56 2.05 
Muscle 1.28 1.5 1.46 1.72 
Pancreas 1.22 1.55 0.92 1.18 
Skin whole body 1.22 1.43 1.49 1.74 
Lymph nodes in ET region 0.89 1.1 1.08 1.34 
Kidneys 0.84 1.06 0.85 1.09 
Colon 0.42 0.54 0.1 0.13 
Salivary glands 0.42 0.51 0.63 0.77 
Extrathoracic (ET) region 0.34 0.41 0.55 0.68 
Small intestine 0.34 0.43 0.28 0.35 
Oral mucosa 0.32 0.38 0.67 0.81 
Eye lenses 0.08 0.05 0.31 0.36 
Eye 0.08 0.1 0.27 0.32 
Brain 0.06 0.08 0.11 0.14 
Effective dose (mSv) 3.34 3.92 3.97 4.70 
(1)Skin, bone marrow and lymph nodes inside the thorax region. 
Organ doses to the gonads (testes / ovaries), prostate / uterus and bladder were each 0.01 mGy. 
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Figure 3: Dose volume histogram (DVH) for a selection of organs resulting from the V1.6 and V2.5 thorax 
protocol (Tables 1 and 2) for the adult male (M) and female (F) ICRP phantoms. 
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3.1.3. Pelvis protocols: 
The doses for the female colon and small intestine were substantially larger than for the male phantom 
with 40% of these organs in the female phantom receiving a dose of about 40 mGy (Figure 4), but differences 
in other organs were less significant. Doses to the majority of organs rose, with the increase in the field size 
of the new protocol (Figure 4). Doses to the ovaries, prostate, uterus, and urinary bladder, which lay within 
the scan fields, increased by 15% or less.  
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Table 5: Organ and effective doses for the adult male and female ICRP phantoms resulting from the V1.6 
and V2.5 pelvis protocol (Tables 1 and 2). 
Pelvis Male (mGy) Female (mGy) 
Organ / Tissue V1.6 V2.5 V1.6 V2.5 
Urinary bladder 44.75 51.38 48.35 54.75 
Prostate / Uterus 34.55 39.28 37.5 42.4 
Bone marrow in field(1) 27.98 32.26 32.1 37.03 
Small intestine 15.01 18.21 24.85 28.74 
Bone marrow (red) whole body 13.08 15.09 14.76 17.04 
Lymph nodes in field(1) 12.21 14.25 12.41 14.81 
Colon 11.2 12.96 27.49 32.97 
Lymph nodes 10.29 12.01 10.64 12.69 
Bone surface 8.33 9.64 9.88 11.39 
Muscle 6.81 8.07 7.87 9.29 
Remainder Tissues 6.8 8.08 8.24 9.72 
Skin in field(1) 5.4 6.35 6.06 7.14 
Skin whole body 4.93 5.8 5.72 6.73 
Gonads (Testes / Ovaries) 3.62 4.74 36.74 42.38 
Kidneys 1.46 1.84 2.41 3.04 
Pancreas 1.16 1.49 2.09 2.64 
Gall bladder 0.83 1.07 1.14 1.44 
Adrenals 0.62 0.74 0.96 1.19 
Stomach 0.6 0.75 1.29 1.61 
Liver 0.49 0.61 0.84 1.04 
Spleen 0.35 0.41 0.73 0.89 
Spinal cord 0.14 0.18 0.21 0.26 
Heart 0.08 0.11 0.11 0.14 
Oesophagus 0.07 0.08 0.08 0.1 
Lung 0.05 0.07 0.09 0.12 
Breast 0.03 0.04 0.04 0.05 
Lymph nodes in TR region 0.02 0.03 0.03 0.04 
Thymus 0.01 0.02 0.02 0.03 
Thyroid 0.01 0.01 0.01 0.02 
Effective dose (mSv) 6.05 7.05 11.30 13.19 
(1)Skin, bone marrow and lymph nodes inside the pelvic region. 
Organ doses to the extrathoracic (ET) region, oral mucosa, lymph nodes in et region, brain, salivary glands, 
eye lenses, and eye were each 0.01 mGy. 
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Figure 4: Dose volume histogram (DVH) for a selection of organs resulting from the V1.6 and V2.5 pelvis 
protocol (Tables 1 and 2) for the adult male (M) and female (F) ICRP phantoms.  
 
The scan protocols implemented in V2.0 are identical to those of V2.5, except that the X1position used 
for the body scan protocols was set to 33 mm compared to 34 mm in V2.5. Therefore, organ and effective 
doses estimated in this study with the V2.5 protocols are expected to be similar to those for V2.0 with 
insignificant differences for the body protocols. 
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3.2. Factors responsible for dose increases in the V2.5 protocols: 
Using the new protocols, exposure factors and field sizes have all been increased. The differences 
between V1.6 and V2.5 scan protocols are the numbers of projections, the mAs values, and the sizes of the 
scan fields used for each version. 
3.2.1. Projection numbers and mAs: 
Although values of mAs per projection were reduced for the V2.5 protocols, the increase of projection 
numbers led to a rise in patient dose. The dose increases for organs that were within scan fields of all the 
protocols were within 2.5%, and this was commensurate with the overall increase in mAs. Figure 5 shows 
DVH comparisons for some organs using the V2.5 projection numbers and mAs values and the V1.6 values. 
The DVHs were obtained for the organs using the V2.5 field size, i.e. the field size was constant. This allows 
the influence of the increased number of projections and mAs on organ doses to be observed. Thus, the use 
of higher projection numbers led to an increased in organ doses because of the increase in mAs. More 
projections help directly to improve the image quality and provide better reconstruction of the volumetric 
images, but the choice of total mAs is a decision based on the balance between the level of image quality 
required and the dose to the patient. The image quality plays a crucial role for soft tissue image matching at 
some sites such as the abdominal region, and it reduces the time required for the treatment verification. 
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Figure 5: A comparison between DVH of some organs resulting from the head (brain), thorax (lung and 
heart), and pelvis (urinary baldder) scan protocols using the V2.5 projection numbers of 500 and 900 and the 
mAs values (Table 2), and those used in V1.6 (367 and 660) (Table 1) for the adult male (M) and female (F) 
ICRP phantoms.  
 
3.2.2. Sizes of the scan fields 
The scan field plays a major role in influencing the doses to some organs. Doses of organs that were 
irradiated fully or partially by the primary beam were increased by (1 to 10)%, (7 to 73)% and (11 to 19)% 
for the head, thorax, and pelvis protocols, respectively, for both phantoms because of the extension in the 
scan field. The doses within parts of several organs were raised and examples are shown in Figure 6. This 
resulted in increases in effective dose for the head, thorax, and pelvis protocols by 0.04 mSv, 0.58 mSv, and 
1.0 mSV for the male phantom, and by 0.06 mSv, 0.73 mSv, and 1.89 mSv for the female phantom, 
respectively for the three protocols. 
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Figure 6: A comparison between DVH of some organs resulting from the head (brain), thorax (lung and 
heart), and pelvis (urinary baldder) scan protocols using the V2.5 scan field (Table 2) and scan fields similar 
to those used in V1.6 protocols (Table 1) for the adult male (M) and female (F) ICRP phantoms.  
 
3.3. Influence of the scan parameters: 
The main aim of developing a new software version is to improve performance of the OBI system in 
terms of obtaining better image quality to aid the precision in setting up the patient on the treatment couch. 
The influence of new scan protocols that were released with new software versions (i.e. upgraded versions) 
on image quality and patient doses have been investigated in several studies (Palm et al., 2010, Ding et al., 
2010, Dufek et al., 2011, Ding and Munro, 2013). These studies showed that the default scan protocols 
implemented in new versions usually played a role in improving the image quality and minimizing organ and 
effective doses. The decrease in the patient dose resulted from using an improved image reconstruction 
algorithm and/or different scans parameters such as lower mAs and kV values. Cheng et al.(2011), for 
example, found that the V1.4.13 scan protocols reduced the effective dose significantly compared to V1.4.11, 
where effective dose of head and pelvic scans were 9.4 mSv and 16 mSv for V1.4.11 compared to 1.6 mSv 
and 8.2 mSv for V1.4.13, respectively. These large reductions arose from the use of lower exposure 
parameters. The head scan of V1.4.11 was acquired with 125 kV and 1300 mAs over a full 360º rotation, 
whereas 100 kV and 720 mAs with a partial scan (200º) were used for that of V1.4.13. The value of the mAs 
was also decreased for the pelvic scan from 1300 mAs to 680 mAs.  
In the present case, however, the new scan protocols deliver a higher dose to the patient. The dose 
resulting from CBCT scans to adjacent organs and tissues is generally smaller than the dose delivered by the 
treatment beam (Siiskonen et al., 2017), but the dose from imaging can be significant. For example, the 
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equivalent dose to the colon resulting from treatment of a prostate cancer patient by 80 Gy using 18 MV 
photon 4-field 3D-Conformal Radiotherapy (3D-CRT) technique was 1.2 Gy for colon (Bezak et al., 2017). 
While guidance of the treatment beam by CBCT scans from this study performed on a daily basis, i.e. a worst 
case scenario, during a treatment of 32 fractions could deliver an additional colon dose of 0.41 Gy to a male 
patient. The trade-off between risk and benefit from the CBCT scans should therefore be considered. Several 
recommendations can be suggested to optimize the dose involved in IGRT procedures, while keeping the 
image quality at an acceptable level that assists the practitioners in setting up the patient precisely and deliver 
the treatment beam: 
(1) Collimation: 
From investigation of the scan parameters presented in Section (3.2), the main reason for the dose 
increase in the V2.5 protocols was found to be the extension of the scan field. This results in greater doses 
from primary and scattered radiation to nearby organs some of which are radio-sensitive and so have higher 
weighting factors for effective dose. For example, extension of the scan field for the pelvis scan raised colon 
dose from 11.20 to 12.96 mGy for the male, and from 27.49 to 32.97 mGy for the female, which made a large 
contribution to increasing the effective dose by ~17% for both phantoms Figure 5. Similarly, lung, stomach, 
and breast are all radio-sensitive, and have an influence on the effective dose from the thorax scan (Table 4). 
Extension of the scan field is necessary for cases where there is a large tumour in the abdominal region 
in order to cover all therapy-relevant structures. By extending the scan field towards the patient’s head, the 
spinal cord (bony structure) is included, which provides better markers for matching compared to soft tissues. 
On the other hand, for cases treated with the stereotactic ablative radiotherapy (SABR) technique targeting a 
small tumour on the lung or prostate, fiducial markers can be inserted into the tumour and used for matching 
with a small field size. A patient-specific field size can be used with the OBI system based on using four 
dynamic blades and tube current modulation (Parsons and Robar, 2016). The dynamic blades adjust the size 
of the scan field during CBCT scans acquisition based on a volume of interest (VOI) specified by the planner. 
The use of this system enhanced contrast-to-noise ratio by a factor of ~2.2 and reduced the scan dose by up 
to 80% as compared to the static blades. 
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In contrast to the OBI system, the XVI system is provided with a series of lead collimators of different 
sizes known as collimator cassettes identified by letters (S, M, or L) and numbers (10, 15, or 20), where the 
letters and numbers are used to identify extension of the field in the lateral and axial directions, respectively 
(Spezi et al., 2009). The choice of collimator is based on the clinical case and size of the patient and can 
reduce the imaging dose for small patients or patients with smaller tumours. Effective doses from XVI scans 
have been reported to vary over the ranges (0.03 to 0.09) mSv, (0.64 to 7.88) mSv, and (0.16 to 7.60) mSv 
for head and neck, thorax, and pelvic scans, respectively (Marchant and Joshi, 2017). The scan parameters, 
including mAs and size of the scan field used for XVI protocols, differ from those used for the OBI. The OBI 
system allows the development of new scan protocols, so establishing small, medium, and large fields, for 
each site taking into account the clinical needs for the treatment as well as the patient size should be 
considered. 
(2) Reduction of mAs value: 
Default scan protocols implemented in the OBI system were provided for scans of the head, thorax and 
pelvic regions. The abdominal region is usually scanned with the pelvis protocol (Tables 1 and 2) as the 
thorax protocol does not provide images of good quality for matching. Therefore, a specific protocol has been 
created for the abdominal region, based on the pelvic protocol (Table 2), in which the mAs has been reduced 
from 1080 mAs to 810 mAs, but the projection numbers maintained at 900 that delivered 0.9 mAs per 
projection. This still provides the level of good image quality required in the lower attenuation abdominal 
organs and tissues, but reduces doses to the colon and stomach. Table 6 lists organ doses resulting from 
abdominal scans performed with the abdomen protocol (810 mAs) and the default pelvis protocol (1080 
mAs). For both scans, the centre of the scan was set up at the mid-point of the pancreas, the position 
commonly used for setting up pancreatic cancer cases. Effective doses from the abdomen protocol are 10.9 
mSv and 11.2 mSv for male and female phantoms, respectively, compared to 14.4 mSv and 14.9 mSv with 
the pelvic protocol. In addition a reduction in the mAs values used for scans routinely, particularly for scans 
that are repeated at regular intervals on individual patients, could be achieved through application of patient 
specific protocols. 
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Table 6: Organ and effective doses for the ICRP adult male and female phantoms resulting from using the 
abdomen protocol with (810 mAs) and the default pelvis protocol with (1080 mAs) (Table 2). Centre of both 
scans was set up at mid of pancreas of both phantoms. 
Abdomen Male (mGy) Female (mGy) 
Organ / Tissue Abdomen  Pelvis  Abdomen  Pelvis  
Stomach 31.68 42.24 39.24 52.31 
Pancreas 31.19 41.58 41.75 55.67 
Kidneys 28.18 37.57 34.8 46.4 
Gall bladder 27.54 36.72 37.09 49.45 
Adrenals 26.82 35.76 33.05 44.07 
Liver 26.07 34.76 32.64 43.52 
Colon 22.03 29.38 15 20 
Spleen 21.69 28.92 27.87 37.17 
Bone marrow in field(1) 19.24 25.66 29.79 39.72 
Small intestine 17.38 23.18 21.38 28.5 
Lymph nodes in field(1) 13.12 17.5 14.57 19.43 
Heart 10.84 14.45 7.6 10.14 
Lymph nodes 10.79 14.39 11.44 15.25 
Spinal cord 8.04 10.71 8.59 11.45 
Bone marrow (red) whole body 7.63 10.17 9.62 12.82 
Skin in field(1) 7.63 10.17 9.1 12.13 
Oesophagus 7.07 9.43 5.81 7.75 
Lung 6.29 8.38 5.34 7.12 
Bone surface 5.38 7.17 6.79 9.05 
Remainder Tissues 5.27 7.03 6.53 8.7 
Breast 4.68 6.25 2.64 3.52 
Muscle 4.45 5.93 5.14 6.85 
Skin whole body 4.31 5.75 4.93 6.58 
Lymph nodes in TR region 2.24 2.98 1.85 2.47 
Thymus 1.46 1.94 1.35 1.81 
Thyroid 0.84 1.12 0.66 0.88 
Urinary bladder 0.75 1 0.97 1.3 
Lymph nodes in ET region 0.27 0.36 0.17 0.22 
Prostate / Uterus 0.26 0.35 0.86 1.15 
Extrathoracic (ET) region 0.09 0.12 0.09 0.12 
Oral mucosa 0.08 0.11 0.12 0.17 
Salivary glands 0.08 0.11 0.09 0.12 
Eye lenses 0.03 0.04 0.04 0.06 
Eye 0.03 0.04 0.06 0.08 
Gonads (Testes / Ovaries) 0.02 0.03 0.92 1.23 
Brain 0.01 0.02 0.02 0.02 
Effective dose (mSv) 10.80 14.40 11.20 14.93 
(1)Skin, bone marrow and lymph nodes inside the abdomen region. 
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(3) Partial rotation technique: 
Use of the posterior partial rotation (200°) technique provides images that are sufficient for matching 
for head and neck patients and reduces the doses to eyes. Figure 7 shows a comparison between DVH for the 
eye and eye lens using the partial and full (360°) rotations. The DVHs show that the dose distribution across 
the eyes is relatively uniform in both cases, but the doses to the eye lenses are less than 30% of those that 
would be delivered from the full rotation. Figure 8 shows the change in dose distribution over the organs and 
tissues in a selected slice of the head resulting from partial Figure 8a and full Figure 8b head scans. In order 
to compare between the different techniques, doses of all voxels for both scans were normalized with respect 
to the maximum voxel dose of the partial scan in the selected slice. Although the maximum voxel dose of 
the full scan is lower by a factor of 0.67, the partial technique reduced eye dose to about one third. Eye lens 
doses from the full rotation scan were 3.68 mGy for male and 3.62 mGy for female, compared to 0.97 mGy, 
and 1.02 mGy, respectively, from the partial rotation (Table 3). 
  
  
Figure 7: Dose volume histogram (DVH) of eye and eye lens using head and neck scan for the adult male 
(M) and female (F) ICRP phantoms using the partial (200) and full (360) rotation scans. 
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Figure 8: A comparsion between dose disbribuions resulting from the head scan over a selected slice of the 
male head using (a) a partial rotation (200º) and (b) a full rotation (360º). Doses of all voxels were noramlized 
with respected to the maxium value in (a).  
 
(4) Inclusion of the imaging dose with the total treatment dose: 
The additional dose from imaging through regular scans could be included in the treatment dose. This 
would require calculation of organ doses by the treatment planning systems and inclusion of the values as a 
part of the daily treatment fraction. Although this approach is possible for MV CBCT scans, the capability 
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of most treatment planning systems in calculating doses in the kV range is limited, except for the Philips 
Pinnacle system (Alaei and Spezi, 2012, Dzierma et al., 2014). The results presented in this study and other 
studies published in the literature and summarized in (Alaei and Spezi, 2015) can be utilized in giving a better 
understanding of the additional dose from imaging received by patients during their course of treatment. The 
results should aid in drawing up appropriate treatment protocols with multiple CBCT scans, and allow the 
practitioners to compare the dose consequences of different imaging modalities and protocols used for IGRT 
procedures. 
4. Conclusion 
Monte Carlo simulations were used to assess organ and effective doses resulting from default scan 
protocols (head, thorax, and pelvis) implemented in V1.6 and V2.5 of the Varian OBI system used in 
conjunction with IGRT. The scan doses resulting from V2.5 protocols were higher than those of the previous 
version. The effective doses for the V2.5 head, thorax, and pelvis protocols were higher than those of the 
previous versions by 14%, 17%, and 16%, respectively, for the male phantom, and by 13%, 18%, and 17%, 
for the female phantom. The extension of the scan field was the main factor responsible for these increases. 
If such changes in protocols are not reviewed and optimized, there is a risk that dose levels will gradually 
creep upwards to obtain better images, without considering optimization. Although the field size extension 
increases the imaging dose, it does play a vital role in determining the precision with which practitioners can 
set up patient treatments. However, use of field sizes tailored to specific patients, reduction of the mAs for 
scans of the abdominal region, use of the posterior partial rotation, and inclusion of the imaging dose into the 
treatment dose should be considered for optimization of the patient dose when using CBCT scans for IGRT 
procedures.  
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